Totipotency/pluripotency and patentability.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18403750.
- Also identified by DOI 10.1634/stemcells.2008-0232.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In their article entitled " Is totipotency of a human cell a sufficient reason to exclude its patentability under the European law" (Stem Cells 2007;25:3026-3028), K.T. Vrtovec and B. Vrtovec conclude that arguments based on differentiation potential should not be an obstacle to patenting human embryonic stem cells (and related cells referred to as totipotent or pluripotent). While concentrating on formal legal aspects, however, these authors fail to consider a major biological and ethical argument already found in the literature, namely that an obstacle to patenting is to be seen in the potential of cells (e.g., of embryonic stem cell lines), if this potential allows (re)constitution of an embryo when tetraploid complementation is performed.
Medical subject headings
- Patents as Topic
- Pluripotent Stem Cells
- Totipotent Stem Cells